ArticleJournal of functional biomaterials2026
Heterologous Fibrin Biopolymer for Post-Extraction Alveolar Bone Healing in Streptozotocin-Induced Diabetic Rats.
Article in Journal of functional biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Type 1 diabetes mellitus (DM1) is characterized by autoimmune destruction of pancreatic β-cells, resulting in insulin deficiency and persistent hyperglycemia, which impair bone metabolism and compromise post-extraction alveolar bone healing. Heterologous fibrin biopolymer (HFB) has previously demonstrated biocompatibility, biodegradability, bioactivity, and osteoconductive properties under normoglycemic conditions. Therefore, the study investigated the association of HFB with post-extraction alveolar bone healing in streptozotocin-induced diabetic rats, using the diabetic blood clot as a biological control. Forty-eight adult male Wistar rats were induced to DM1 by a single intraperitoneal injection of streptozotocin (52 mg/kg). Animals were included after confirmation of hyperglycemia (fasting blood glucose ≥ 250 mg/dL) measured seven days after STZ administration: blood clot (BCG;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.